+

WO1998001114A1 - Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug - Google Patents

Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug Download PDF

Info

Publication number
WO1998001114A1
WO1998001114A1 PCT/EP1997/003250 EP9703250W WO9801114A1 WO 1998001114 A1 WO1998001114 A1 WO 1998001114A1 EP 9703250 W EP9703250 W EP 9703250W WO 9801114 A1 WO9801114 A1 WO 9801114A1
Authority
WO
WIPO (PCT)
Prior art keywords
granulate
cellulose
fast
tablets
water
Prior art date
Application number
PCT/EP1997/003250
Other languages
French (fr)
Inventor
Bernardus Leonardus Johannes Dijkgraaf
Aart Mühlenbruch
Original Assignee
Yamanouchi Europe B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998001114(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to IL12736497A priority Critical patent/IL127364A/en
Priority to CA002258841A priority patent/CA2258841C/en
Priority to SI9730487T priority patent/SI0910344T1/en
Priority to AT97929241T priority patent/ATE237314T1/en
Priority to HU9903308A priority patent/HU225115B1/en
Priority to JP50470198A priority patent/JP4159607B2/en
Priority to NZ333247A priority patent/NZ333247A/en
Priority to EP97929241A priority patent/EP0910344B1/en
Priority to AU33421/97A priority patent/AU731276B2/en
Application filed by Yamanouchi Europe B.V. filed Critical Yamanouchi Europe B.V.
Priority to BRPI9710181-8A priority patent/BR9710181B1/en
Priority to UA99020610A priority patent/UA61917C2/en
Priority to DE69720995T priority patent/DE69720995T2/en
Priority to SK1767-98A priority patent/SK284175B6/en
Priority to EA199900075A priority patent/EA001537B1/en
Priority to PL97330958A priority patent/PL188235B1/en
Priority to DK97929241T priority patent/DK0910344T3/en
Publication of WO1998001114A1 publication Critical patent/WO1998001114A1/en
Priority to NO986157A priority patent/NO320767B1/en
Priority to BG103047A priority patent/BG64114B1/en
Priority to HK00100533A priority patent/HK1021511A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a granulate, containing an active ingredient, having a solubility in water of 1 :>10, in admixture with a water dispersible cellulose and fast- disintegrating and dissolving compositions, containing the said granulate.
  • US 491 1921 discloses tablets, containing a high dose of ibuprofen.
  • the tablets could be prepared by conventional wet granulation of the drug, a binder and a wet granulation binding agent. Although a fast-release of the active ingredient could be reached, tablets did not disintegrate rapidly.
  • the tablets were prepared either by slugging or by the conventional wet granulation technique, using water or a 2.5 wt% solution of polyvinylpyrrolidone in water. Very fast disintegration times could be reached by tablets prepared by the slugging method only, provided also that alginic acid was incorporated in the granulate. When these techniques were applied to e.g. amoxicillin, also an antibiotic compound, no fast-disintegrating tablets could be obtained.
  • US patent 1560475 discloses tablets containing more than 90% by weight of an orally active cephalosporin and consequently less than 10 wt% of excipients (binder, disintegrant and lubricant).
  • the tablets can be prepared by admixing the cephalosporin and excipients and then compressing the mixture, but preferably the tablets are prepared by dissolving or dispersing the binder in water or a suitable organic solvent and using this liquid to granulate the cephalosporin. The dried granules are then mixed with the disintegrant and the lubricant and compressed into tablets.
  • the disintegration time of such tablets as measured in distilled water at 37°C ranged from 2 minutes to 13 minutes.
  • DE-2259646 discloses tablets containing about 90% of a cephalosporin compound and about 10% of excipients (crystalline cellulose, ultraamylopectin and a lubricant).
  • the tablets are prepared by mixing the above ingredients, making a dry granulate and compressing the granules so obtained into tablets. The tablets were said to disintegrate in artificial gastric juice at 37°C within 3 minutes.
  • EP-0200252 discloses tablets containing 80-98% of a mixture, consisting of trimethoprim or a salt thereof and a sulfonamide or a salt thereof in a ratio between 1 : 20 and 20 : 1, and an ion-exchange compound of the artificial resin type, such as Amberlite® IRP 88.
  • the tablets are prepared by a wet granulation technique using a solution containing a wet granulation binding agent in ethanol or a mixture of ethanol and water. Disintegration times were reported to be less than 1 minute in general, but the teachings of this application appeared to be not applicable to other drugs or combinations of drugs.
  • a formulation technique which is generally applicable to different drugs, having a solubility in water of less than 10% is disclosed in EP-0330284-B.
  • the drug is blended with 20-100 wt% of a cellulose product, which is microcrystalline cellulose, microfme cellulose or a mixture thereof, and granulated with an aqueous solution, containing up to 0.5 wt% of a wet granulation binding agent, all percentages based on the weight of the active ingredient. After drying and sieving the granules they may be blended with suitable excipients, such as disintegrants, lubricants and flavours, to obtain fast-disintegrating tablets.
  • suitable excipients such as disintegrants, lubricants and flavours
  • EP-0281200-B which describes fast-disintegrating tablets, containing an amphoteric beta-lactam antibiotic, 24-70 wt% of a first disintegrant, which is microcrystalline cellulose and or microfme cellulose, and a second disintegrant. Disintegration times were reported to be within one minute in general. The bioavailability of e.g. amoxicillin trihydrate showed to be as good as that of a commercially available suspension and was independent of the way of administering the tablet (as a suspension after having allowed the tablet to disintegrate in water or as a swallowable tablet). However, in the present inventors' experience this formulation technique appeared to be not applicable for the preparation of fast-disintegrating and fast-dissolving tablets, containing a higher amount of active ingredient and a consequently considerably lower amount of the cellulose product.
  • WO 92/19227 discloses tablet formulations, having a high drug content.
  • the tablets were prepared by dry compaction techniques, including the preparation of the granulate. Although apparently fast-disintegrating tablets could be obtained, it was not clear which method was used for the assessment and which requirements were to be met. No results of dissolution studies were provided.
  • the problem to be solved by the present invention was to provide a composition or manufacturing method, which would be generally applicable to all kinds of active ingredients having a solubility in water of less than 10%, in order to obtain fast-disintegrating and fast- disssolving compositions, containing a high amount of the active ingredient, while using conventional production equipment.
  • the object of the present invention is to provide a granulate, containing an active ingredient, having a solubility in water of 1 :>10, in admixture with ⁇ 15 wt%, most preferably 2-5 wt%, of a water dispersible cellulose, the percentage based on the weight of the said active ingredient.
  • Another object of the present invention is to provide fast-disintegrating and fast- dissolving compositions, containing the said granulate.
  • the water dispersible cellulose to be used is also known as "microcrystalline cellulose and carboxymethyl cellulose sodium", e.g. in the U.S. Pharmacopoeia/National Formulary.
  • Microcrystalline cellulose is a partially purified depolymerised form of ⁇ -cellulose and is obtained by treating pulps derived from fibrous plant material with dilute mineral acid solutions. The acid preferentially attacks the less ordered or amorphous regions of the cellulose polymer chain, thereby exposing and freeing the crystalline sites which form cellulose crystallite aggregates. The reaction mixture is washed to remove the degraded byproducts, the resulting wet-cake freed of water and spray-dried to form dry porous particles having a broad size distribution.
  • Microcrystalline cellulose is a white, odorless, tasteless, relatively free-flowing powder, insoluble in water, organic solvents, dilute alkalies and dilute acids. It finds wide use as a pharmaceutical excipient, viz. as a binder/ diluent in the manufacture of tablets by direct compression and wet granulation, as a tablet disintegrant, as a tablet glidant/ anti-adherent and as a capsule diluent. Microcrystalline cellulose is commercially available in different particle size grades with different properties, e.g. Avicel® PH 101 and 102. Carboxymethyl cellulose sodium is prepared by the action of sodium monochloro acetate on alkalised cellulose.
  • the cross-linked product finds use as a tablet disintegrant.
  • the water dispersible celluloses are colloidal forms of microcrystalline cellulose, prepared by chemical depolymerisation of highly purified wood pulp, the original crystalline areas of the fibres being combined with sodium carboxymethyl cellulose and spray-dried. These also find wide use as a pharmaceutical and cosmetic excipient, viz.
  • the water dispersible celluloses are also regarded as excellent excipients in compositions, which are prepared by wet granulation and subsequent extrusion and spheronisation, because the sodium carboxymethyl cellulose component improves the binding properties and the plasticity of the mass to be extruded.
  • the water dispersable celluloses thus can be advantageously used in the preparation of compositions having a sustained-release of the active ingredient.
  • the Avicel® RC 581 type is used and most advantageously the Avicel® RC 591 type is incorporated in the granulate.
  • the water dispersible celluloses can be used in an amount up to ⁇ 15 wt%, based on the weight of the active ingredient, but preferably the said cellulose is used in a concentration of between 1 and 7.5 wt% and more advantageously in a concentration ranging from 2 to 5 wt%, all percentages based on the weight of the active ingredient.
  • the preparation of a granulate out of an active ingredient and corresponding amounts of microcrystalline cellulose and sodium carboxymethyl cellulose respectively did not result in fast-disintegrating and fast-dissolving compositions.
  • the active ingredients, to be incorporated in the granulate have a solubility in water of 1 :>10 at room temperature, but preferably the solubility is 1 :>100.
  • the active ingredient is a drug which has to be administered in a high doses to be effective.
  • antimicrobial compounds in general, selected from the group of beta-lactam compounds, such as the penicillins (amoxicillin, ampicillin) and cephalosporins (cefaclor); the group of macrolides, such as erythromycin and josamycin; the group of sulphonamides, such as sulphamethoxazole; the group of hydroxyquinolones and quinolones, such as ciprofloxacin; the group of imidazoles and nitroimidazoles, such as metronidazole and tinidazole; and various other compounds, such as nalidixic acid, and nitrofurantoin.
  • beta-lactam compounds such as the penicillins (amoxicillin, ampicillin) and cephalosporins (cefaclor)
  • macrolides such as erythromycin and josamycin
  • sulphonamides such as sulphamethoxazole
  • antacids such as hydrotalcite
  • analgesic and anti-inflammatory drugs such as ibuprofen, acetaminophen and acetylsalicylic acid
  • antidiabetic agents such as tolbutamide
  • antimalarials such as amodiaquine hydrochloride
  • tuberculostatics and tuberculocides such as rifampicin
  • anticonvulsants such as carbamazepine
  • dopaminergic agents such as levodopa.
  • the active ingredient is a non-drug, but a compound which is able to enhance the efficacy of a drug if co-administered (either simultaneously or consecutively) with it.
  • a beta-lactamase inhibitor such as clavulanic acid or a pharmaceutically acceptable salt thereof, which showed a significantly improvement of the efficacy of a beta-lactam antibiotic compound.
  • the high active ingredient content of the granulate also allows for combining active ingredients, such as drugs, in the same granulate, if no objections as to incompatibilities arise.
  • the granulates according to the present invention are prepared according to conventional wet granulation methods, e.g. as taught by I.M. Jalal et al.
  • a suitable mixer which may be a planetary mixer, a high shear or a high speed mixer. Mixing times depend on the specific apparatus used.
  • water or an aqueous solution is added until the material is sufficiently moistened. This may be done in the mixer used for blending the components or alternatively the powder blend may be transferred to a fluidised bed granulator, wherein the aqueous solution is sprayed onto the materials.
  • the amount of water used may range from 20 to 30 wt%, based on the weight of the granulate.
  • the wet mass is passed through a first screen and subsequently further dried in a fluidized bed dryer at an air inlet temperature of between 40 and 60°C. After drying the granules until the required free moisture content, these are passed through a second screen. Alternatively the wet mass is transferred to a fluidized bed dryer without wet screening. After drying the granules are passed through a first and a second screen and optionally a third screen respectively.
  • the granulates according to the invention have sufficient to good flow properties. Due to a good bulk volume and a proper Hausner ratio they can be easily processed into compositions. Disintegration and dissolution behaviour of the granulates are also satisfactory.
  • the granulates according to the invention are very versatile in their applications.
  • the granulates can be filled into capsules or sachets.
  • the compositions, based on the above granulate preferably contain the granulate in an amount of > 80 wt% in order WO 98/01114 _g_ PCT/EP97/03250 to obtain high-dosed compositions.
  • blending of a granulate containing a particular active ingredient with another active ingredient external to the granulate can be very favourable in case a combination of drugs or a combination of a drug and a compound enhancing the drug's activity is to be considered.
  • the granulate can also be incorporated in a dosage- form together with a greater part of excipients. This might be very favourable in case taste- masking of an active ingredient is required.
  • the granulate is advantageously blended with a first disintegrant and a second disintegrant.
  • the first disintegrant is preferably a cellulose product, which is microcrystalline cellulose (Avicel® PH 101, Avicel® PH 102), microfine cellulose or a mixture thereof.
  • the second disintegrant may be starch, such as Star-X 1500®, or a starch derivative, such as sodium starch glycolate, but is preferably selected from the group of superdisintegrants, such as cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose.
  • Both the first and the second disintegrant are advantageously added in an amount ranging from about 2, e.g. 1.5 wt%, to 8 wt%, more preferably 3-6 wt%, the percentage based on the weight of the composition.
  • the ratio of the amount of the first and the second disintegrant in the composition may range from ⁇ 4: 1 to 1 :4, but preferably is 1 : 1.
  • the compositions may additionally contain flavours, sweetening agents, such as saccharinic acid, the sodium salt thereof or aspartame, lubricants, such as colloidal silicon dioxide, stearic acid or a salt thereof, but preferably such excipients arc added in an amount of less than 4 wt%, the percentage based on the weight of the composition.
  • fast-disintegrating and fast-dissolving compositions can be prepared out of two granulates, containing a different active ingredient. It can also be advantageous to prepare a granulate out of some of the excipients to be added to the granulate according to the invention. E.g. by means of dry granulating methods a granulate can be advantageously prepared out of the flavours, sweetening agents and one or both of the disintegrants.
  • the granulate can be blended with a drug or a compound which enhances the activity of the active ingredient incorporated in the granulate, such as a beta-lactamase inhibitor in case the intra-granular active ingredient is a beta-lactam compound.
  • fast disintegration is meant a disintegration time in water of room temperature (20°C) of less than 2 minutes and preferably less than one minute.
  • the method according to the European Pharmacopoeia is used however with a further modification of the movement (22 mm instead of 55 mm), simulating a users' situation.
  • Fast dissolution is to be considered as >95% of the drug dissolved in a suitable dissolution medium, e.g. as prescribed in the U.S. Pharmacopoeia 1995 for each particular drug, of 37°C after 30 minutes.
  • Preferably 90% of the drug has been dissolved after 10 minutes (same conditions).
  • compositions according to the present invention show many advantages.
  • an amoxicillin- and a cefaclor-containing tablet according to the present invention either taken as such or after prior dispersal in water, have proved to be equivalent to commercially available compositions.
  • the considerable variation in disintegration time and dissolution rate between compositions, containing a different medicament in a similar carrier, as shown by the prior art compositions described by Jalal et al. has been reduced.
  • By using the high-dosed granulate a considerable reduction of the volume of the dosage-form has been achieved.
  • the reduced size is desirable both from a manufacturing and handling standpoint and a patient acceptability standpoint.
  • Example 1 970 g of cefaclor (as monohydrate) and 30 g of dispersible cellulose (Avicel®RC591) were mixed for 5 minutes in a planetary mixer. Gradually about 320 ml of water was added to this blend and mixing was continued for another 5 minutes. The wet granulate was dried in a fluidised bed dryer at an air inlet temperature of 50 °C and subsequently sieved through a 1.00 mm and 0.630 mm screen respectively.
  • a granulate and tablets were prepared out of the above components according to the methods described in examples 1 and 2.
  • the tablets so obtained had the following characteristics:
  • Amoxicillin (as trihydrate) 86.9 % dispersible cellulose (Avicel®RC591) 2.6 % cross-linked polyvinylpyrrolidone 3.8 % microcrystalline cellulose 3.8 % flavours 1.6 % sweetening agent 1.0 % lubricant 0.4 %
  • a granulate and tablets were prepared out of the above components according to the methods described in examples 1 and 2.
  • the tablets obtained in this way had the following characteristics: disintegration time (in water of 20° C) 48-50 seconds Dissolution 98.5% of amoxicillin dissolved after 30 minutes Mean tablet weight 1330 mg Hardness 20kP Friability ⁇ 0.01%
  • Example 5 A granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the same components as mentioned in example 4, but amoxicillin trihydrate was also substitued by another drug selected from ampicillin anhydrate, acetaminophen, sulphamethoxazole, ibuprofen and ciprofloxacine.
  • the tablets obtained in this way had the following characteristics:
  • a granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the same components as mentioned in example 4, but amoxicillin trihydrate was also substituted by another drug selected from ampicillin anhydrate, sulphamethoxazole, erythromycine ethyl succinate and ciprofloxacine.
  • the tablets obtained in this way had the following characteristics:
  • Example 7 A granulate and tablets were prepared according to the methods described in examples
  • a granulate and tablets were prepared according to the methods described in examples
  • the tablets so obtained had a disintegration time in water of 20°C which was 92 seconds.
  • the observed hardness of the tablet was 7 kP.
  • a granulate and tablets were prepared according to the methods described in examples 1 and 2.
  • the tablets so obtained had the following characteristics:
  • a granulate and tablets were prepared according to the methods described in examples 1 and 2.
  • the tablets so obtained had the following characteristics:
  • a granulate and tablets were prepared according to the methods described in examples
  • the tablets so obtained had a disintegration time in water of 20°C which was 80 seconds.
  • the observed hardness of the tablet was 6 kP.
  • a granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the components as mentioned in example 4, but the ratio of amoxicillin trihydrate and dispersible cellulose (Avicel® RC-591) in the granulate was varied.
  • the tablets so obtained had the following characteristics:
  • a granulate and tablets were prepared according to the methods described in examples
  • a first granulate was made out of 300 g of amoxicillin trihydrate and dispersible cellulose (Avicel® RC-591) according to the method described in example 1.
  • a second granulate was made by blending microcrystalline cellulose (59.5 wt%), flavours (23.3 wt%) and a sweetening agent (5.5 wt%), compressing tablets having a hardness of 1.5-2 kP out of the blend and breaking up the same tablets to form a granulate by means of a Frewitt oscillating granulator.
  • the first and second granulate were blended and subsequently mixed with cross-linked polyvinylpyrrolidone and a lubricant, whereafter tablets were compressed out of the mixture so obtained.
  • the tablets had the following characteristics:
  • a granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the components as mentioned in example 4, but the second extra-granular disintegrant cross-linked polyvinylpyrrolidone was substituted by another disintegrant, selected from starch (Star-X 1500®), sodium starch glycolate, low-substituted hydroxypropyl cellulose and maize starch.
  • the tablets so obtained had the following characteristics:

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Jellies, Jams, And Syrups (AREA)

Abstract

A granulate, containing an active ingredient, having a solubility in water of 1:>10, in admixture with ≤15 wt.% of a water dispersible cellulose, is provided for the preparation of fast-disintegrating and fast-dissolving compositions.

Description

GRANULATE FOR THE PREPARATION OF FAST-DISINTEGRATING AND FAST- DISSOLVING COMPOSITIONS CONTAINING A HIGH AMOUNT OF DRUG
The present invention relates to a granulate, containing an active ingredient, having a solubility in water of 1 :>10, in admixture with a water dispersible cellulose and fast- disintegrating and dissolving compositions, containing the said granulate.
BACKGROUND OF THE INVENTION
It is well-known that for an effective treatment of diseases high doses of drugs and especially of antimicrobial compounds may have to be administered. In addition thereto there is a need to reduce the dosing frequency from 4 or 3 times daily to twice or once daily in order to increase patient compliance. The daily dose of a drug may thus be divided over 1 or 2 instead of 3 or 4 doses, which means that the amount of drug per dosage-form has to be increased. Some drugs, depending on their potency and pharmacokinetic properties can be suitably incorporated in so-called modified-release preparations. Other drugs, such as e.g. amoxicillin, appear to provide the best bioavailability when incorporated in compositions having an immediate release of the active ingredient only (Scand. J. Gastroentererol. (1996) 11(1), pages 49-53). Since it is not convenient for a patient to take at the same time two or more small preparations containing the same medicament instead of one large preparation, especially not for the elderly who normally have to take multiple medications, there always has been a need for such easily swallowable dosage-forms, containing a maximum amount of drug and a minimum amount of excipients and still having the desired fast-disintegrating and fast-dissolving properties. Numerous attempts to realise such dosage-forms have been undertaken since the seventies, but as it appeared the compositions and manufacturing methods developed were applicable to certain selected drugs only.
I.M. Jalal et al. in J. Pharm Sci (1972) 61:9, pages 1466-1467, disclose tablets, containing 80% of a drug which is magnesium hydroxide, sulphadiazine or acetaminophen, and 20% of a binder which is Avicel® RC581 (microcrystalline cellulose and sodium carboxymethyl cellulose). Tablets were prepared by mixing the drug and the said binder, granulating the blend with water, drying the granules and compressing these into tablets. Disintegration times varied from 0.8 minutes (magnesium hydroxide) to 3.5 minutes (sulphadiazine). In the present inventors' experience it has become clear that the results greatly depend on the properties of the drug: e.g. when they applied the above method to prepare tablets containing 80 wt% of amoxicillin trihydrate, a disintegration time of 12'J2 minutes was observed, tablets containing ibuprofen disintegrated after more than 5 minutes and tablets containing sulphamethoxazole required 35 minutes to disintegrate in water. The results, as obtained by Jalal for sulphadiazine and acetaminophen, could be rather well reproduced by the present inventors. O'Connor et al. in Drug Devel. Ind. Pharm (1985) U(9&10) pages 1837-1857 evaluated in-vitro drug release profiles for uncoated pellets, consisting of different drugs and diluents (microcrystalline cellulose and two types of water dispersible cellulose) in varying ratio's and prepared by wet granulation and subsequent extrusion and spheronisation. However, fast dissolution rates could not be observed at all. G. Barato et al. in Labo-Pharma (1984) 22, no 342 pages 401-403 describe granulates, consisting of a high amount of a drug having a water solubility of 1 :>10, carboxymethyl cellulose and polyvinylpyrrolidone and being prepared by conventional wet granulation. Tablets made out of the granulate were reported to disintegrate after 13 minutes only.
In DE-4310963 the preparation of alleged fast-release tablets of propafenon-HCl was disclosed. According to figure 7 the percentage release of active ingredient after 30 minutes was 10% only.
US 491 1921 discloses tablets, containing a high dose of ibuprofen. The tablets could be prepared by conventional wet granulation of the drug, a binder and a wet granulation binding agent. Although a fast-release of the active ingredient could be reached, tablets did not disintegrate rapidly.
A.A. Chalmers et al. in J. Pharm. Pharmac. (1976) ___ pages 234-238, disclose tablet formulations containing a high amount (>90%) of oxytetracycline and optionally intragranular microcrystalline cellulose (7.2%) and/or alginic acid (2.7%). The tablets were prepared either by slugging or by the conventional wet granulation technique, using water or a 2.5 wt% solution of polyvinylpyrrolidone in water. Very fast disintegration times could be reached by tablets prepared by the slugging method only, provided also that alginic acid was incorporated in the granulate. When these techniques were applied to e.g. amoxicillin, also an antibiotic compound, no fast-disintegrating tablets could be obtained.
US patent 1560475 discloses tablets containing more than 90% by weight of an orally active cephalosporin and consequently less than 10 wt% of excipients (binder, disintegrant and lubricant). The tablets can be prepared by admixing the cephalosporin and excipients and then compressing the mixture, but preferably the tablets are prepared by dissolving or dispersing the binder in water or a suitable organic solvent and using this liquid to granulate the cephalosporin. The dried granules are then mixed with the disintegrant and the lubricant and compressed into tablets. However, the disintegration time of such tablets as measured in distilled water at 37°C ranged from 2 minutes to 13 minutes.
DE-2259646 discloses tablets containing about 90% of a cephalosporin compound and about 10% of excipients (crystalline cellulose, ultraamylopectin and a lubricant). The tablets are prepared by mixing the above ingredients, making a dry granulate and compressing the granules so obtained into tablets. The tablets were said to disintegrate in artificial gastric juice at 37°C within 3 minutes.
EP-0200252 discloses tablets containing 80-98% of a mixture, consisting of trimethoprim or a salt thereof and a sulfonamide or a salt thereof in a ratio between 1 : 20 and 20 : 1, and an ion-exchange compound of the artificial resin type, such as Amberlite® IRP 88. The tablets are prepared by a wet granulation technique using a solution containing a wet granulation binding agent in ethanol or a mixture of ethanol and water. Disintegration times were reported to be less than 1 minute in general, but the teachings of this application appeared to be not applicable to other drugs or combinations of drugs.
A formulation technique which is generally applicable to different drugs, having a solubility in water of less than 10% is disclosed in EP-0330284-B. The drug is blended with 20-100 wt% of a cellulose product, which is microcrystalline cellulose, microfme cellulose or a mixture thereof, and granulated with an aqueous solution, containing up to 0.5 wt% of a wet granulation binding agent, all percentages based on the weight of the active ingredient. After drying and sieving the granules they may be blended with suitable excipients, such as disintegrants, lubricants and flavours, to obtain fast-disintegrating tablets. A specific example thereof is disclosed in EP-0281200-B, which describes fast-disintegrating tablets, containing an amphoteric beta-lactam antibiotic, 24-70 wt% of a first disintegrant, which is microcrystalline cellulose and or microfme cellulose, and a second disintegrant. Disintegration times were reported to be within one minute in general. The bioavailability of e.g. amoxicillin trihydrate showed to be as good as that of a commercially available suspension and was independent of the way of administering the tablet (as a suspension after having allowed the tablet to disintegrate in water or as a swallowable tablet). However, in the present inventors' experience this formulation technique appeared to be not applicable for the preparation of fast-disintegrating and fast-dissolving tablets, containing a higher amount of active ingredient and a consequently considerably lower amount of the cellulose product.
WO 92/19227 discloses tablet formulations, having a high drug content. The tablets were prepared by dry compaction techniques, including the preparation of the granulate. Although apparently fast-disintegrating tablets could be obtained, it was not clear which method was used for the assessment and which requirements were to be met. No results of dissolution studies were provided.
The problem to be solved by the present invention was to provide a composition or manufacturing method, which would be generally applicable to all kinds of active ingredients having a solubility in water of less than 10%, in order to obtain fast-disintegrating and fast- disssolving compositions, containing a high amount of the active ingredient, while using conventional production equipment.
SUMMARY OF THE INVENTION
The object of the present invention is to provide a granulate, containing an active ingredient, having a solubility in water of 1 :>10, in admixture with < 15 wt%, most preferably 2-5 wt%, of a water dispersible cellulose, the percentage based on the weight of the said active ingredient. Another object of the present invention is to provide fast-disintegrating and fast- dissolving compositions, containing the said granulate.
DETAILED DESCRIPTION OF THE INVENTION
It has now been found that by making a blend of an active ingredient, having a solubility in water of 1 :>10, in admixture with < 15 wt% of a water dispersible cellulose, the percentage based on the weight of the active ingredient, granulating the blend with water or an aqueous solution and subsequent drying of the wet granulate a granulate is obtained which can be advantageously used for the preparation of fast-disintegrating and fast-dissolving compositions.
The water dispersible cellulose to be used is also known as "microcrystalline cellulose and carboxymethyl cellulose sodium", e.g. in the U.S. Pharmacopoeia/National Formulary. Microcrystalline cellulose is a partially purified depolymerised form of α-cellulose and is obtained by treating pulps derived from fibrous plant material with dilute mineral acid solutions. The acid preferentially attacks the less ordered or amorphous regions of the cellulose polymer chain, thereby exposing and freeing the crystalline sites which form cellulose crystallite aggregates. The reaction mixture is washed to remove the degraded byproducts, the resulting wet-cake freed of water and spray-dried to form dry porous particles having a broad size distribution. Microcrystalline cellulose is a white, odorless, tasteless, relatively free-flowing powder, insoluble in water, organic solvents, dilute alkalies and dilute acids. It finds wide use as a pharmaceutical excipient, viz. as a binder/ diluent in the manufacture of tablets by direct compression and wet granulation, as a tablet disintegrant, as a tablet glidant/ anti-adherent and as a capsule diluent. Microcrystalline cellulose is commercially available in different particle size grades with different properties, e.g. Avicel® PH 101 and 102. Carboxymethyl cellulose sodium is prepared by the action of sodium monochloro acetate on alkalised cellulose. It is a white to faintly yellow, colorless, hygroscopic powder or granular material and is commercially available in a number of different grades with respect to degree of substitution, viscosity, particle size etc.. It is well- known as a suspending and/or viscosity increasing agent and a wet granulation binding agent. The cross-linked product finds use as a tablet disintegrant. The water dispersible celluloses are colloidal forms of microcrystalline cellulose, prepared by chemical depolymerisation of highly purified wood pulp, the original crystalline areas of the fibres being combined with sodium carboxymethyl cellulose and spray-dried. These also find wide use as a pharmaceutical and cosmetic excipient, viz. as an oil-in-water emulsifier, an emulsion or foam stabilising agent, as a suspending agent in pharmaceutical suspensions (ready-made as well as reconstitutable suspension) and as a thickening agent. The water dispersible celluloses are also regarded as excellent excipients in compositions, which are prepared by wet granulation and subsequent extrusion and spheronisation, because the sodium carboxymethyl cellulose component improves the binding properties and the plasticity of the mass to be extruded. The water dispersable celluloses thus can be advantageously used in the preparation of compositions having a sustained-release of the active ingredient. Four types of the said celluloses have been marketed under the trade names Avicel® RC-501 (containing 7.1-11.9% of sodium carboxylmethyl cellulose), Avicel® RC-581 (containing 8.3-13.8% of sodium carboxymethyl cellulose), Avicel® RC-591 (containing 8.3-13.8% of sodium carboxymethyl cellulose) and Avicel® CL-61 1 (containing 11.3-18.8% of sodium carboxymethyl cellulose). All types are hygroscopic powders, which are insoluble in organic solvents and dilute acids, and partially soluble in both dilute alkali and water (due to the sodium carboxymethyl cellulose component). In view of the above-mentioned properties, it is surprising that all four types may be used to prepare the granulate according to the invention, which allows for the preparation of fast-disintegrating compositions, having a fast release of the active ingredient. Of the above-mentioned grades preferably the Avicel® RC 581 type is used and most advantageously the Avicel® RC 591 type is incorporated in the granulate. The water dispersible celluloses can be used in an amount up to < 15 wt%, based on the weight of the active ingredient, but preferably the said cellulose is used in a concentration of between 1 and 7.5 wt% and more advantageously in a concentration ranging from 2 to 5 wt%, all percentages based on the weight of the active ingredient. Surprisingly, in the present inventors' experience the preparation of a granulate out of an active ingredient and corresponding amounts of microcrystalline cellulose and sodium carboxymethyl cellulose respectively, did not result in fast-disintegrating and fast-dissolving compositions.
The active ingredients, to be incorporated in the granulate have a solubility in water of 1 :>10 at room temperature, but preferably the solubility is 1 :>100. Advantageously the active ingredient is a drug which has to be administered in a high doses to be effective. Examples of such drugs are antimicrobial compounds in general, selected from the group of beta-lactam compounds, such as the penicillins (amoxicillin, ampicillin) and cephalosporins (cefaclor); the group of macrolides, such as erythromycin and josamycin; the group of sulphonamides, such as sulphamethoxazole; the group of hydroxyquinolones and quinolones, such as ciprofloxacin; the group of imidazoles and nitroimidazoles, such as metronidazole and tinidazole; and various other compounds, such as nalidixic acid, and nitrofurantoin. However other drugs, not belonging to the antimicrobial compounds, can also be succesfiilly granulated according to the present invention: antacids, such as hydrotalcite, analgesic and anti-inflammatory drugs, such as ibuprofen, acetaminophen and acetylsalicylic acid, antidiabetic agents, such as tolbutamide, antimalarials, such as amodiaquine hydrochloride, tuberculostatics and tuberculocides, such as rifampicin, anticonvulsants, such as carbamazepine, and dopaminergic agents, such as levodopa. Alternatively the active ingredient is a non-drug, but a compound which is able to enhance the efficacy of a drug if co-administered (either simultaneously or consecutively) with it. An example thereof is a beta-lactamase inhibitor, such as clavulanic acid or a pharmaceutically acceptable salt thereof, which showed a significantly improvement of the efficacy of a beta-lactam antibiotic compound. The high active ingredient content of the granulate also allows for combining active ingredients, such as drugs, in the same granulate, if no objections as to incompatibilities arise.
The granulates according to the present invention are prepared according to conventional wet granulation methods, e.g. as taught by I.M. Jalal et al. Preferably the active ingredient and water dispersible cellulose are blended in a suitable mixer, which may be a planetary mixer, a high shear or a high speed mixer. Mixing times depend on the specific apparatus used. Thereafter water or an aqueous solution is added until the material is sufficiently moistened. This may be done in the mixer used for blending the components or alternatively the powder blend may be transferred to a fluidised bed granulator, wherein the aqueous solution is sprayed onto the materials. The amount of water used may range from 20 to 30 wt%, based on the weight of the granulate. After partial drying the wet mass is passed through a first screen and subsequently further dried in a fluidized bed dryer at an air inlet temperature of between 40 and 60°C. After drying the granules until the required free moisture content, these are passed through a second screen. Alternatively the wet mass is transferred to a fluidized bed dryer without wet screening. After drying the granules are passed through a first and a second screen and optionally a third screen respectively. Whereas many of the above-mentioned active ingredients have unsatisfactory flow- properties, the granulates according to the invention have sufficient to good flow properties. Due to a good bulk volume and a proper Hausner ratio they can be easily processed into compositions. Disintegration and dissolution behaviour of the granulates are also satisfactory. The granulates according to the invention are very versatile in their applications. Optionally after addition of suitable excipients, such as lubricants, flow-promotors, anti- adherents, etc., the granulates can be filled into capsules or sachets. The compositions, based on the above granulate, preferably contain the granulate in an amount of > 80 wt% in order WO 98/01114 _g_ PCT/EP97/03250 to obtain high-dosed compositions. However, due to the high active ingredient content and limited number of excipients required for obtaining fast-disintegrating and fast-dissolving compositions, blending of a granulate containing a particular active ingredient with another active ingredient external to the granulate can be very favourable in case a combination of drugs or a combination of a drug and a compound enhancing the drug's activity is to be considered. It goes without saying that the granulate can also be incorporated in a dosage- form together with a greater part of excipients. This might be very favourable in case taste- masking of an active ingredient is required.
In order to prepare fast-disintegrating and fast-dissolving compositions, containing a high amount of drug, the granulate is advantageously blended with a first disintegrant and a second disintegrant. The first disintegrant is preferably a cellulose product, which is microcrystalline cellulose (Avicel® PH 101, Avicel® PH 102), microfine cellulose or a mixture thereof. The second disintegrant may be starch, such as Star-X 1500®, or a starch derivative, such as sodium starch glycolate, but is preferably selected from the group of superdisintegrants, such as cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose. Both the first and the second disintegrant are advantageously added in an amount ranging from about 2, e.g. 1.5 wt%, to 8 wt%, more preferably 3-6 wt%, the percentage based on the weight of the composition. The ratio of the amount of the first and the second disintegrant in the composition may range from <4: 1 to 1 :4, but preferably is 1 : 1. The compositions may additionally contain flavours, sweetening agents, such as saccharinic acid, the sodium salt thereof or aspartame, lubricants, such as colloidal silicon dioxide, stearic acid or a salt thereof, but preferably such excipients arc added in an amount of less than 4 wt%, the percentage based on the weight of the composition.
Alternatively, fast-disintegrating and fast-dissolving compositions can be prepared out of two granulates, containing a different active ingredient. It can also be advantageous to prepare a granulate out of some of the excipients to be added to the granulate according to the invention. E.g. by means of dry granulating methods a granulate can be advantageously prepared out of the flavours, sweetening agents and one or both of the disintegrants. Optionally the granulate can be blended with a drug or a compound which enhances the activity of the active ingredient incorporated in the granulate, such as a beta-lactamase inhibitor in case the intra-granular active ingredient is a beta-lactam compound. By fast disintegration is meant a disintegration time in water of room temperature (20°C) of less than 2 minutes and preferably less than one minute. For the assessment thereof the method according to the European Pharmacopoeia is used however with a further modification of the movement (22 mm instead of 55 mm), simulating a users' situation. Fast dissolution is to be considered as >95% of the drug dissolved in a suitable dissolution medium, e.g. as prescribed in the U.S. Pharmacopoeia 1995 for each particular drug, of 37°C after 30 minutes. Preferably 90% of the drug has been dissolved after 10 minutes (same conditions).
The compositions according to the present invention show many advantages. In a bioequivalence study an amoxicillin- and a cefaclor-containing tablet according to the present invention, either taken as such or after prior dispersal in water, have proved to be equivalent to commercially available compositions. Furthermore, the considerable variation in disintegration time and dissolution rate between compositions, containing a different medicament in a similar carrier, as shown by the prior art compositions described by Jalal et al., has been reduced. By using the high-dosed granulate a considerable reduction of the volume of the dosage-form has been achieved. The reduced size is desirable both from a manufacturing and handling standpoint and a patient acceptability standpoint. The advantages thereof are manifold: a patient can more easily swallow a tablet composition, as a consequence of which patient compliance will be increased. Due to the reduction of the amount of excipients to be used, the new compositions also have advantages both from an economical point of view, such as considerable savings on production costs and a reduction of packaging materials, and from an environmental point of view, such as a reduction of waste from e.g. aluminum and polyvinyl-chloride, which packaging materials cannot be recycled. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be readily apparent to those of ordinary skill in the art in the light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit and the scope of the appended claims. The following examples further illustrate the invention. WO 98/01114 . j Q. PCT/EP97/03250
EXAMPLES
Example 1 970 g of cefaclor (as monohydrate) and 30 g of dispersible cellulose (Avicel®RC591) were mixed for 5 minutes in a planetary mixer. Gradually about 320 ml of water was added to this blend and mixing was continued for another 5 minutes. The wet granulate was dried in a fluidised bed dryer at an air inlet temperature of 50 °C and subsequently sieved through a 1.00 mm and 0.630 mm screen respectively.
Example 2
864 g of the granulate obtained according to example 1 was mixed with 98 g of a mixture of microcrystalline cellulose and cross-linked polyvinylpyrrolidone (1 :1), flavours and sweetening agents in a TURBULA-mixer for 10 minutes. After a lubricant was added mixing was continued for another 3 minutes and the mixture was compressed into tablets, having a mean weight of 625 mg.
The tablets obtained had the following characteristics:
Friability <0.01% Hardness 6.9 kP
Mean tablet weight 627 mg Disintegration time (in water of 20°C) 22 seconds Dissolution 98% cefaclor dissolved after 10 minutes
99% cefaclor dissolved after 30 minutes yo/uiiii ι ι PCT/EP97/03250
Example 3
Cefaclor monohydrate 524.0 mg dispersible cellulose (Avicel®RC591) 15.7 mg microcrystalline cellulose 13.5 mg low-substituted hydroxypropyl cellulose 13.5 mg flavour 9.1 mg sweetening agent 9.1 mg lubricants 9.2 mg
A granulate and tablets were prepared out of the above components according to the methods described in examples 1 and 2. The tablets so obtained had the following characteristics:
Friability <0.01% Hardness 7.4 kP
Mean tablet weight 597 mg Disintegration time (in water of 20°C) 100 seconds Dissolution 92 % cefaclor dissolved after 10 minutes
96 % cefaclor dissolved after 30 minutes
Example 4
Amoxicillin (as trihydrate) 86.9 % dispersible cellulose (Avicel®RC591) 2.6 % cross-linked polyvinylpyrrolidone 3.8 % microcrystalline cellulose 3.8 % flavours 1.6 % sweetening agent 1.0 % lubricant 0.4 % A granulate and tablets were prepared out of the above components according to the methods described in examples 1 and 2. The tablets obtained in this way had the following characteristics: disintegration time (in water of 20° C) 48-50 seconds Dissolution 98.5% of amoxicillin dissolved after 30 minutes Mean tablet weight 1330 mg Hardness 20kP Friability <0.01%
Example 5 A granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the same components as mentioned in example 4, but amoxicillin trihydrate was also substitued by another drug selected from ampicillin anhydrate, acetaminophen, sulphamethoxazole, ibuprofen and ciprofloxacine. The tablets obtained in this way had the following characteristics:
drug hardness (kP disintegration dissolution disssolwtion time in water of (% after 10 (% after 0
20°C (s minutes) minutes amoxicillin trihydrate 7.5 45 92.0 97.2 ampicillin anhydrate 7.1 41 86.7 97.2 acetaminophen 3.7 25 93.7 102.0 sulphamethoxazole 7.3 36 66.9 86.2 (after 20 minutes) ibuprofen 5.5 54 98.0 101.8 ciprofloxacine 6.0 32 95.9 99.3
Note: the dissolution o "all tablets, exc ;ept for the amoxici 11 in-containing oi αes, was assessec according to the methods described in the USP '95. Example 6
Like in example 5 a granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the same components as mentioned in example 4, but amoxicillin trihydrate was also substituted by another drug selected from ampicillin anhydrate, sulphamethoxazole, erythromycine ethyl succinate and ciprofloxacine. The tablets obtained in this way had the following characteristics:
drug hardness (kP) disintegration disintegration time in water of time in water of
20°C (s) 20°C (s) amoxicillin trihydrate 10.4 47 14.7 47 ampicillin anhydrate 10.6 40 15.4 59 sulphamethoxazole 10.1 57 13.8 66 erythromycine ethyl 10.6 67 13.9 11 1 succinate ciprofloxacine 9.1 34 14.1 65
Example 7 A granulate and tablets were prepared according to the methods described in examples
1 and 2 out of the components as mentioned in example 4, but another type of dispersible cellulose was used. The tablets obtained in this way had the following characteristics:
type of dispersible cellulose hardness (kP) disintegration time in water of 20°C (s)
Avicel® RC-501 6.8 77
Avicel® CL-61 1 6.4 93 WO 98/01114 _j4_ PCT/EP97/03250
Example 8
granulate (= amoxicillin trihydrate/ dispersible cellulose (Avicel®RC581) 98/2) 89.6 % cross-linked polyvinyl pyrrolidone 3.9 % microcrystalline cellulose 3.9 % flavours 1.6 % sweetening agent 1.0 %
A granulate and tablets were prepared according to the methods described in examples
1 and 2. The tablets so obtained had a disintegration time in water of 20°C which was 92 seconds. The observed hardness of the tablet was 7 kP.
Example 9
granulate (= amoxicillin trihydrate/ dispersible cellulose (Avicel®RC581 ) 97/3) 84.75 % cross-linked polyvinyl pyrrolidone 4 % microcrystalline cellulose 1 1 % lubricant 0.25 %
A granulate and tablets were prepared according to the methods described in examples 1 and 2. The tablets so obtained had the following characteristics:
hardness (kP) disintegration time in water of 20°C (s)
6 102 12 120 Example 10
granulate (= amoxicillin trihydrate/ dispersible cellulose (Avicel®RC581 ) 96/4) 84 % cross-linked polyvinyl pyrrolidone 4 % microcrystalline cellulose 8.7 % lubricant 3.3 %
A granulate and tablets were prepared according to the methods described in examples 1 and 2. The tablets so obtained had the following characteristics:
hardness (kP) disintegration time in water of 20°C (s)
5 94
9 90
15 1 15
Example 11
granulate (= amoxicillin trihydrate/ dispersible cellulose (Avicel®RC581 ) 92/8) 89.3 % cross-linked polyvinyl pyrrolidone 4.0 % microcrystalline cellulose 6.4 % lubricant 0.2 %
A granulate and tablets were prepared according to the methods described in examples
1 and 2. The tablets so obtained had a disintegration time in water of 20°C which was 80 seconds. The observed hardness of the tablet was 6 kP.
Example 12
A granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the components as mentioned in example 4, but the ratio of amoxicillin trihydrate and dispersible cellulose (Avicel® RC-591) in the granulate was varied. The tablets so obtained had the following characteristics:
ratio amoxicillin trihvdrate/ dispersible hardness (kP) disintegration time in cellulose (Avicel® RC-591) water of 20°C fs)
95/5 7.3 77
92.5/7.5 7.1 87
85/15 6.5 127
Example 13
granulate (= amoxicillin trihydrate/ dispersible cellulose (Avicel®RC591) 95/5) 84.1 % cross-linked polyvinyl pyrrolidone 6.3 % microcrystalline cellulose 6.3 % flavours 1.6 % sweetening agent 1.0 % lubricant 0.7 %
A granulate and tablets were prepared according to the methods described in examples
1 and 2 out of the above components. The tablets so obtained had the following characteristics:
hardness (kP) disintegration time in water of 20°C (s)
7 52-56 11 56-61 18 58-62
Example 14
A first granulate was made out of 300 g of amoxicillin trihydrate and dispersible cellulose (Avicel® RC-591) according to the method described in example 1. A second granulate was made by blending microcrystalline cellulose (59.5 wt%), flavours (23.3 wt%) and a sweetening agent (5.5 wt%), compressing tablets having a hardness of 1.5-2 kP out of the blend and breaking up the same tablets to form a granulate by means of a Frewitt oscillating granulator. The first and second granulate were blended and subsequently mixed with cross-linked polyvinylpyrrolidone and a lubricant, whereafter tablets were compressed out of the mixture so obtained. The tablets had the following characteristics:
Composition of tablet % % % % granulate 1 79.6 84.6 89.5 94.5 granulate 2 12.5 9.4 6.4 3.1 cross-linked polyvinylpyrrolidone 7.4 5.6 3.8 1.9 lubricant 0.4 0.4 0.4 0.5 properties of tablet hardness (kP) 5.0 7.3 7.5 6.8 disintegration time in water of 20°C 31.8 43.8 45.0 92.3
Example 15
A granulate and tablets were prepared according to the methods described in examples 1 and 2 out of the components as mentioned in example 4, but the second extra-granular disintegrant cross-linked polyvinylpyrrolidone was substituted by another disintegrant, selected from starch (Star-X 1500®), sodium starch glycolate, low-substituted hydroxypropyl cellulose and maize starch. The tablets so obtained had the following characteristics:
second extragranular hardness (kP disintegration time in water disintegrant of 20°C ( ) starch (Star-X 1500®) 5.8 73 sodium starch glycolate 4.8 124 low-substituted 5.1 53 hydroxypropyl cellulose maize starch 5.9 71

Claims

WO 98/01114 _ j g. PCT/EP97/03250CLAIMS
1. Granulate, containing an active ingredient, having a solubility in water of 1 :>10, in admixture with a water dispersible cellulose, which is a microcrystalline cellulose and sodium carboxymethyl cellulose, characterised in that the water dispersible cellulose is present in an amount of < 15 wt%, the percentage based on the weight of the active ingredient.
2. Granulate according to claim 1, characterised in that it contains 1-7.5 wt% of the water dispersible cellulose.
3. Granulate according to claim 1 or 2, characterised in that it contains 2-5 wt% of the water dispersible cellulose.
4. Granulate according to any one of claims 1-3, characterised in that the water dispersible cellulose is Avicel® RC-591.
5. Granulate according to any one of claims 1-4, characterised in that it has been prepared by a conventional wet granulation technique.
6. Fast-disintegrating and fast-dissolving composition, containing at least one granulate according to any one of claims 1-5 in admixture with pharmaceutically acceptable excipients and optionally a drug or a compound, enhancing the activity of the active ingredient incorporated in the granulate.
7. Composition according to claim 6, characterised in that one or more of the granulates according to any one of claims 1 -5 are present in a total amount of > 80 wt%, in admixture with 2-8 wt% of a first disintegrant and 2-8 wt% of a second disintegrant, the percentages based on the weight of the composition.
8. Composition according to claim 7, characterised in that the first disintegrant is microcrystalline cellulose, microfme cellulose or a mixture thereof and the second disintegrant is starch or a starch derivative, cross-linked polyvinylpyrrolidone or low- substituted hydroxypropyl cellulose.
9. Composition according to claim 7 or 8, characterised in that the first disintegrant and the second disintegrant are present in a ratio of 1 : 1.
PCT/EP1997/003250 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug WO1998001114A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DK97929241T DK0910344T3 (en) 1996-07-03 1997-06-19 Granules for the preparation of rapidly decaying and fast-soluble compositions with a high drug content
BRPI9710181-8A BR9710181B1 (en) 1996-07-03 1997-06-19 granules for the preparation of rapidly disintegrating and rapidly dissolving compositions containing a large amount of drug.
SI9730487T SI0910344T1 (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
AT97929241T ATE237314T1 (en) 1996-07-03 1997-06-19 GRANULES FOR THE PREPARATION OF RAPID DISRUPTING AND RAPID DISSOLVING PREPARATIONS WITH A HIGH CONTENT OF ACTIVE INGREDIENTS
HU9903308A HU225115B1 (en) 1996-07-03 1997-06-19 Granuls for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP50470198A JP4159607B2 (en) 1996-07-03 1997-06-19 Granules for the production of fast disintegrating and fast dissolving compositions containing large amounts of drug
NZ333247A NZ333247A (en) 1996-07-03 1997-06-19 Granulate containing an active ingredient and a water dispersible cellulose useful for the preparation of fast-disintegrating and fast-dissolving compositions
EP97929241A EP0910344B1 (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
AU33421/97A AU731276B2 (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
IL12736497A IL127364A (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
DE69720995T DE69720995T2 (en) 1996-07-03 1997-06-19 GRANULES FOR THE PREPARATION OF QUICK DISASSEMBLING AND QUICK RELEASING PREPARATIONS WITH A HIGH PROPORTION OF ACTIVE SUBSTANCE
CA002258841A CA2258841C (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
UA99020610A UA61917C2 (en) 1996-07-03 1997-06-19 Granulate and fast-disintegrating and fast-dissolving compositions
SK1767-98A SK284175B6 (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
EA199900075A EA001537B1 (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a great amount of medicaments
PL97330958A PL188235B1 (en) 1996-07-03 1997-06-19 Granulate for use in production of a rapidly disintegrating and dissolving composition containing large amount of a drug
NO986157A NO320767B1 (en) 1996-07-03 1998-12-28 Granules for the preparation of fast disintegrating and fast soluble compositions containing a high amount of active ingredient
BG103047A BG64114B1 (en) 1996-07-03 1998-12-30 Granulate for the preparation of quick decomposition and quick dissolving compositions having high medicamentous form content
HK00100533A HK1021511A1 (en) 1996-07-03 2000-01-28 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP96201829 1996-07-03
EP96201829.7 1996-07-03
US08/770,421 1996-12-20
US08/770,421 US5837292A (en) 1996-07-03 1996-12-20 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug

Publications (1)

Publication Number Publication Date
WO1998001114A1 true WO1998001114A1 (en) 1998-01-15

Family

ID=8224133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/003250 WO1998001114A1 (en) 1996-07-03 1997-06-19 Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug

Country Status (36)

Country Link
US (1) US5837292A (en)
EP (1) EP0910344B1 (en)
JP (1) JP4159607B2 (en)
CN (1) CN1131025C (en)
AR (1) AR008252A1 (en)
AT (1) ATE237314T1 (en)
AU (1) AU731276B2 (en)
BG (1) BG64114B1 (en)
BR (1) BR9710181B1 (en)
CA (1) CA2258841C (en)
CO (1) CO4890859A1 (en)
CZ (1) CZ295893B6 (en)
DE (1) DE69720995T2 (en)
DK (1) DK0910344T3 (en)
EA (1) EA001537B1 (en)
EG (1) EG23814A (en)
ES (1) ES2197351T3 (en)
HK (1) HK1021511A1 (en)
HU (1) HU225115B1 (en)
ID (1) ID17128A (en)
IL (1) IL127364A (en)
JO (1) JO1969B1 (en)
MY (1) MY116124A (en)
NO (1) NO320767B1 (en)
NZ (1) NZ333247A (en)
PE (1) PE89798A1 (en)
PL (1) PL188235B1 (en)
PT (1) PT910344E (en)
SI (1) SI0910344T1 (en)
SK (1) SK284175B6 (en)
TN (1) TNSN97114A1 (en)
TR (1) TR199802762T2 (en)
TW (1) TW473392B (en)
UA (1) UA61917C2 (en)
WO (1) WO1998001114A1 (en)
ZA (1) ZA975848B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063970A1 (en) * 1998-06-11 1999-12-16 Pharmacia & Upjohn Company Delavirdine tablet formulation
WO2001012162A1 (en) * 1999-08-11 2001-02-22 EGIS Gyógyszergyár Rt. Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof
JP2002514600A (en) * 1998-05-09 2002-05-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Oral drug with reproducible release of active substance, comprising gatifloxacin or a pharmaceutically acceptable salt or hydrate thereof
JP2002540153A (en) * 1999-03-26 2002-11-26 ビオシント・ソシエタ・ペル・アチオニ Granules high in L-carnitine or alkanoyl L-carnitine
EP1285649A1 (en) * 2001-08-23 2003-02-26 Cimex AG Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers
EP1368003A1 (en) * 2001-02-05 2003-12-10 R.P. Scherer Technologies, Inc. Methods and compositions for reducing the taste of pharmaceutically active agents
WO2003103674A1 (en) * 2002-06-06 2003-12-18 Bernard Charles Sherman Tablets comprising ciprofloxacin hydrochloride
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
WO2011152808A1 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Formulation comprising cefpodoxime proxetil and clavulanic acid
EP2397161A1 (en) * 2009-02-12 2011-12-21 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
WO2013151517A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Tablet formulations comprising cefpodoxime proxetil and clavulanic acid
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US20090060995A1 (en) * 2005-01-13 2009-03-05 Kamalinder Kaur Singh Dispersible sustained release pharmaceutical compositions
WO2000069417A1 (en) * 1999-05-14 2000-11-23 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
AR028253A1 (en) * 2000-03-16 2003-04-30 Pfizer Prod Inc INHIBITORS OF THE GLUCOGENO FOSFORILASA
FR2816507B1 (en) * 2000-11-16 2003-02-28 Ethypharm Lab Prod Ethiques MICROGRANULES BASED ON ACTIVE PRINCIPLE, PROCESS FOR THE MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAID MICROGRANULES
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
EP1469829B1 (en) * 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
WO2004014337A2 (en) * 2002-08-02 2004-02-19 Ranbaxy Laboratories Limited A process for the preparation of dispersible tablet of cephalexin
JP4702763B2 (en) * 2003-07-30 2011-06-15 塩野義製薬株式会社 Stable tablets containing crystalline cellulose
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
HUE043958T2 (en) * 2003-09-12 2019-09-30 Amgen Inc Rapid dissolution formulation comprising cinacalcet hcl
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
JP5201819B2 (en) * 2006-11-22 2013-06-05 エスエス製薬株式会社 Solid composition
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CN101912373B (en) * 2010-08-24 2012-01-04 北京京丰制药有限公司 Stable cefeclor dispersible tablet and preparation method thereof
JP2015063521A (en) * 2013-09-02 2015-04-09 科研製薬株式会社 Tablet having high drug content and method for producing the same
CN106255512B (en) * 2014-04-21 2021-01-01 株式会社大赛璐 Disintegrating granule composition containing microfibrous cellulose
CN110051639B (en) * 2019-03-15 2021-08-31 河北嘉迈医药科技有限公司 Rapidly disintegrating nicergoline tablet and preparation method thereof
CN117683469B (en) * 2023-10-24 2024-08-27 绍兴拓邦新能源股份有限公司 Alkaline polishing solid additive for back surface of crystalline silicon wafer and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318621A1 (en) * 1975-07-24 1977-02-18 Takeda Chemical Industries Ltd L-ASCORBIC ACID GRANULES AND TABLETS AND METHOD FOR PREPARING THEM
EP0281200A1 (en) * 1987-03-02 1988-09-07 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
EP0330284A2 (en) * 1988-02-25 1989-08-30 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
US4911921A (en) * 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations
DE4310963A1 (en) * 1993-04-03 1994-10-06 Knoll Ag Extended-release tablet of beta-phenylpropiophenone derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
BE795766A (en) * 1972-02-22 1973-08-22 Lilly Co Eli PROPOXYPHENE DELAY NAPSYLATE PARTICLES AND PROCESS FOR MANUFACTURING SUCH PARTICLES
DE2259646C2 (en) * 1972-12-06 1984-11-22 Hoechst Ag, 6230 Frankfurt High-dose tablets of cephalosporin derivatives, as well as processes for their manufacture
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
JPS58403B2 (en) * 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
GB1560475A (en) * 1975-10-11 1980-02-06 Lilly Industries Ltd Pharmaceutical formulation
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
EP0200252B1 (en) * 1985-05-02 1999-03-10 Yamanouchi Europe B.V. Tablets comprising trimethoprim and a sulfonamide
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
DE4122217C2 (en) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Process for the preparation of mechanically stable, well decomposing compressed products from small active substance-containing moldings

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318621A1 (en) * 1975-07-24 1977-02-18 Takeda Chemical Industries Ltd L-ASCORBIC ACID GRANULES AND TABLETS AND METHOD FOR PREPARING THEM
EP0281200A1 (en) * 1987-03-02 1988-09-07 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
EP0330284A2 (en) * 1988-02-25 1989-08-30 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
US4911921A (en) * 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations
DE4310963A1 (en) * 1993-04-03 1994-10-06 Knoll Ag Extended-release tablet of beta-phenylpropiophenone derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARATO G. ET AL: "Evaluation of apparatus for granule production. A practical example in the pharmaceutical industry", LABO-PHARMA-PROBL. TECH., vol. 342, 1984, pages 401 - 401, XP000613532 *
ELBERS J.A.C. ET AL: "Effect of amount and composition of granulation liquid on mixing, extrusion and spheronization", DRUG DEV. IND. PHARM., vol. 18, no. 5, 1992, pages 501 - 517, XP000613400 *
O'CONNOR R.E. ET AL: "Spheronization II : drug release from drug diluent mixtures", DRUG DEV. IND. PHARM. SCI., vol. 11, no. 9-10, 1985, PHILADELPHIA, pages 1837 - 1857, XP000613242 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514600A (en) * 1998-05-09 2002-05-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Oral drug with reproducible release of active substance, comprising gatifloxacin or a pharmaceutically acceptable salt or hydrate thereof
US6177101B1 (en) 1998-06-11 2001-01-23 Pharmacia & Upjohn Company Delavirdine high strength tablet formulation
WO1999063970A1 (en) * 1998-06-11 1999-12-16 Pharmacia & Upjohn Company Delavirdine tablet formulation
KR100724016B1 (en) * 1998-06-11 2007-05-31 파마시아 앤드 업존 캄파니 엘엘씨 Delavirdin tablet formulation
JP2002540153A (en) * 1999-03-26 2002-11-26 ビオシント・ソシエタ・ペル・アチオニ Granules high in L-carnitine or alkanoyl L-carnitine
JP4637367B2 (en) * 1999-03-26 2011-02-23 ビオシント・ソシエタ・ペル・アチオニ L-carnitine or alkanoyl L-carnitine high content granule
WO2001012162A1 (en) * 1999-08-11 2001-02-22 EGIS Gyógyszergyár Rt. Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof
RU2251420C2 (en) * 1999-08-11 2005-05-10 Эгиш Дьёдьсердьяр Рт. Ciprofloxacin-containing pharmaceutical composition and method for its obtaining
EP1368003A4 (en) * 2001-02-05 2004-05-12 Scherer Technologies Inc R P Methods and compositions for reducing the taste of pharmaceutically active agents
EP1368003A1 (en) * 2001-02-05 2003-12-10 R.P. Scherer Technologies, Inc. Methods and compositions for reducing the taste of pharmaceutically active agents
EP1285649A1 (en) * 2001-08-23 2003-02-26 Cimex AG Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers
WO2003017985A1 (en) * 2001-08-23 2003-03-06 Cimex Ag Bilayered dispersible tablet formulation comprising amoxycillin and clavulanate in separate layers
WO2003103674A1 (en) * 2002-06-06 2003-12-18 Bernard Charles Sherman Tablets comprising ciprofloxacin hydrochloride
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US11617751B2 (en) 2006-07-06 2023-04-04 Bayer Pharma AG Pharmaceutical composition containing a tetrahydrofolic acid
EP2397161A1 (en) * 2009-02-12 2011-12-21 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
EP2397161A4 (en) * 2009-02-12 2013-06-05 Fuji Chem Ind Co Ltd Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
WO2011152808A1 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Formulation comprising cefpodoxime proxetil and clavulanic acid
WO2013151517A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Tablet formulations comprising cefpodoxime proxetil and clavulanic acid

Also Published As

Publication number Publication date
JP2000513727A (en) 2000-10-17
PL188235B1 (en) 2004-12-31
TNSN97114A1 (en) 2005-03-15
AU3342197A (en) 1998-02-02
ATE237314T1 (en) 2003-05-15
PL330958A1 (en) 1999-06-21
SI0910344T1 (en) 2003-08-31
ZA975848B (en) 1999-04-12
SK284175B6 (en) 2004-10-05
TR199802762T2 (en) 1999-03-22
JP4159607B2 (en) 2008-10-01
NO986157L (en) 1999-02-01
NO320767B1 (en) 2006-01-23
BR9710181A (en) 1999-08-10
SK176798A3 (en) 2000-04-10
BR9710181B1 (en) 2009-08-11
DK0910344T3 (en) 2003-07-07
MY116124A (en) 2003-11-28
EP0910344A1 (en) 1999-04-28
EG23814A (en) 2007-09-12
JO1969B1 (en) 1997-12-15
HUP9903308A3 (en) 2001-03-28
EA001537B1 (en) 2001-04-23
IL127364A0 (en) 1999-10-28
PT910344E (en) 2003-09-30
ES2197351T3 (en) 2004-01-01
AR008252A1 (en) 1999-12-29
CO4890859A1 (en) 2000-02-28
PE89798A1 (en) 1999-01-12
CZ295893B6 (en) 2005-11-16
ID17128A (en) 1997-12-04
CN1131025C (en) 2003-12-17
HU225115B1 (en) 2006-06-28
HK1021511A1 (en) 2000-06-16
AU731276B2 (en) 2001-03-29
CA2258841C (en) 2006-05-30
TW473392B (en) 2002-01-21
DE69720995D1 (en) 2003-05-22
CZ699A3 (en) 1999-04-14
EP0910344B1 (en) 2003-04-16
BG64114B1 (en) 2004-01-30
EA199900075A1 (en) 1999-06-24
NO986157D0 (en) 1998-12-28
UA61917C2 (en) 2003-12-15
US5837292A (en) 1998-11-17
CN1224348A (en) 1999-07-28
IL127364A (en) 2003-04-10
BG103047A (en) 1999-07-30
NZ333247A (en) 2000-07-28
DE69720995T2 (en) 2003-11-13
CA2258841A1 (en) 1998-01-15
HUP9903308A2 (en) 2000-03-28

Similar Documents

Publication Publication Date Title
EP0910344B1 (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
CA2477890C (en) Immediate release pharmaceutical granule compositions and a continuous process for making them
JPH10504818A (en) Pharmaceutical formulation containing amoxicillin and potassium clavulanate
SK282594B6 (en) Process for preparing a tablet formulation
EP1233768A1 (en) Carvedilol methanesulfonate
US20080069879A1 (en) Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
ZA200309289B (en) Oxcarbazepine dosage forms.
AU759517B2 (en) Compositions comprising cefuroxime axetil
WO2008077591A2 (en) Pharmaceutical formulation comprising neurokinin antagonist
EP2844245A1 (en) New formulation
JPH10504295A (en) Pharmaceutical prescription
SK50442006A3 (en) Pellets containing venlafaxine hydrochloride
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
JPH08310969A (en) Solid pharmaceutical composition and its preparation
KR100475260B1 (en) Granulate for the preparation of fast-disintegrating and fast-dissolvingcompositions containing a high amount of drug
JP2813792B2 (en) Preparation for oral administration of irsogladine maleate and its production method
MXPA06010805A (en) Clarithromycin extended release formulation.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97196057.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 333247

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2258841

Country of ref document: CA

Ref document number: 2258841

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/010685

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 176798

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1997929241

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019980710856

Country of ref document: KR

Ref document number: 1998/02762

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PV1999-6

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 199900075

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: PV1999-6

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997929241

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980710856

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997929241

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019980710856

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-6

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载